Background: This prospective, randomized, double-blind study was undertaken to compare prophylactic nicardipine infusion with esmolol infusion to determine their effects on the control of hemodynamic response during emergence from total intravenous anesthesia (TIVA) with propofol and remifentanil.
INTRODUCTION
Emergence from general anesthesia and tracheal extubation is often accompanied with tachycardia and hypertension [1] . It has been reported that patients experience 37%, 50% and 55% increases in systolic blood pressure (BP), diastolic BP, and heart rate (HR), respectively, during tracheal extubation [2] . Accordingly, it is imperative that these hemodynamic responses be controlled in patients with unstable cardiovascular status to prevent complications.
Total intravenous anesthesia (TIVA) with propofol and remifentanil allows rapid and predictable titration of anesthesia, and swift consciousness and respiration recovery even after prolonged anesthesia. However, despite these potential advantages of TIVA, postoperative complications such as hypertension may be common [3] . In addition, the incidence of hypertension after TIVA has been reported to be higher than inhalation anesthesia with fentanyl [4] . Several studies have addressed the effectivenesses of esmolol or nicardipine with respect to the blunting of hemodynamic alterations associated with emergence from anesthesia [5] [6] [7] [8] .
This prospective, randomized and double-blind study was designed to compare the hemodynamic effects of nicardipine and esmolol infusions during emergence from TIVA with propofol and remifentanil. Anesthesia was maintained using propofol and remifentanil.
MATERIALS AND METHODS

After
Effect-site target concentrations of propofol were adjusted to maintain BIS between 40−50 and those of remifentanil were adjusted using clinical signs and hemodynamic measurements.
Inadequate anesthesia was defined as an increase in MBP or HR of more than 20% of the preanesthetic value. If inadequate anesthesia or hypotension (systolic BP ＜ 85 mmHg) occurred when BIS was within the recommended range, the target concentration of remifentanil was increased or decreased, respectively. Preoperative infiltration of 0.75% ropivacaine was performed at the incision site. During operations, lactated Ringer's solution administration was administered at 4 ml/kg/hr.
Patients were randomly assigned to one of three groups: 1) 2 μg/kg/min nicardipine (the nicardipine group) [9] , 2) 250 μg/ kg/min esmolol (the esmolol group) [10] , or 3) 10−14 ml/hr of isotonic saline (the placebo group). Randomization was performed using computer-generated codes that were kept in sealed opaque envelopes. An anesthetic nurse unaware of treatment assignments prepared study drugs as 20 ml solutions in identical black syringes labeled with infusion rate per hour of the drug according to patient weight. Nicardipine was diluted to 500 μg/ml and esmolol to 50 mg/ml. Anesthesiologists and investigators who collected postoperative data at postanesthesia care unit (PACU) and wards were also unaware of randomization details and study drugs allocations.
Propofol infusion was stopped approximately 10 min before the anticipated end of surgery (skin closure). Thereafter, the study medications were continuously infused at the indicated rates until 15 min after PACU transfer. At the end of surgery Data are mean ± SD or numbers (n). Patients in the nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol respectively during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. Data are numbers of patients (n). The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. *One patient suffers from bradycardia after esmolol infusion. This case is excluded from the analysis of mean blood pressure and heart rate profiles. 
RESULTS
Of the 132 enrolled patients, 3 patients were excluded from the analysis because of hypotension (1 in the nicardipine group and 1 in the esmolol group) and bradycardia (1 in the esmolol group). Demographic data for the remaining 129 patients are shown in Table 1 . No significant differences were apparent among the esmolol, nicardipine, and placebo group with regard to demographic characteristics or anesthetic drug requirements.
The number of patients administered with atropine, postoperative ketorolac, and nicardipine (1 mg) were also comparable in the three groups (Table 2) .
Pre-induction and baseline MBP values were similar among the three groups (Fig. 1) . Compared to baseline, increases in Fig. 2 . Perioperative changes in heart rate. The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. Dotted line: at the end of surgery, remifentanil infusion is discontinued and the neuromuscular blockade is reversed. Ext: extubation, P: at ward, B: before study drug infusion, 1 min (T1), 2 min (T2), 3 min (T3), 4 min (T4), 5 min (T5), 6 min (T6), 7 min (T7), 8 min (T8), 9 min (T9), 10 min (T10) after study drug infusion, 5 min (P5), 10 min (P10), 15 min (P15) after transfer to PACU, 5 min (D5), 10 min (D10) after discontinuing study medication, immediately (W1) and 6 hours (W6h) after ward transfer. *P ＜ 0.05: HR is significantly lower in the esmolol group than in the nicardipine group. † P ＜ 0.05: HR is significantly lower in the esmolol group than in the placebo group. Fig. 3 . Perioperative changes in rate-pressure product. The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr of normal saline. Dotted line: at the end of surgery, remifentanil infusion is discontinued and the neuromuscular blockade is reversed. Ext: extubation, B: before study drug infusion start, 1 min (T1), 2 min (T2), 3 min (T3), 4 min (T4), 5 min (T5), 6 min (T6), 7 min (T7), 8 min (T8), 9 min (T9), 10 min (T10) after study drug infusion, 5 min (P5), 10 min (P10), 15 min (P15) after transfer to PACU, 5 min (D5), 10 min (D10) after discontinuing study medication, immediately (W1) and 6 hours (W6h) after ward transfer. *P ＜ 0.05: RPP is significantly lower in the esmolol group than in the placebo group. Rate-pressure product = systolic BP × HR.
MBP were observed from 10 min after infusion start in nicardipine group, 7 min in esmolol and in placebo group. From 10 min after transfer to PACU until 10 min after infusion stop, MBP was significantly lower in the nicardipine group than in the esmolol group (P ＜ 0.05).
Pre-induction and baseline HR values were comparable among the three groups (Fig. 2) . Compared to baseline, increases in HR were observed from 10 min after infusion start in esmolol group, 7 min in nicardipine and in placebo group. HR was significantly lower in the esmolol group than in the nicardipine group from 6 min after drug infusion. No differences in HR were observed between the nicardipine and placebo group at any time.
RPP was significantly lower in the esmolol group than in the placebo group from 8 min after drug infusion (Fig. 3) , but the esmolol and nicardipine groups were comparable. BIS values were similar at each time point among the three groups (Fig. 4) .
DISCUSSION
Clinical studies have demonstrated that emergence from TIVA with propofol and remifentanil as compared with balanced anesthesia using inhalation anesthetics and opioid, is accompanied by an increased incidence of hypertension requiring antihypertensive medication to maintain MBP within 20% of baseline [4, 11] . Moreover, a higher incidence of hypertension after remifentanil-based anesthesia has been previously described and was attributed to inadequate analgesia after stopping remifentanil infusion [12] . Therefore, anesthesiologists using TIVA should consider employing antihypertensive therapy more liberally at around the end of surgical procedures.
The recommended infusion rate of esmolol is reported to be 200−300 μg/kg/min [10, 13] and that of nicardipine to be 1− 3 μg/kg/min [9, 14] . Thus, we chose median values of these ranges as infusion rates for this study (esmolol 250 μg/kg/min, nicardipine 2 μg/kg/min). A small loading dose (e.g., esmlolol Fig. 4 . Perioperative changes in electroencephalographic (EEG) bispectral index (BIS) in the three groups from baseline (mean ± SD). The nicardipine and esmolol groups receive a continuous infusion of 2 μg/kg/min nicardipine or 250 μg/kg/min esmolol during emergence from total intravenous anesthesia, while the placebo group receives 10−14 ml/hr normal saline. Dotted line: at the end of surgery, remifentanil infusion is discontinued and the neuromuscular blockade is reversed. No differences are evident among the three groups. Ext: extubation, B: before study drug infusion start, 1 min (T1), 2 min (T2), 3 min (T3), 4 min (T4), 5 min (T5), 6 min (T6), 7 min (T7), 8 min (T8), 9 min (T9), 10 min (T10) after study drug infusion. 500 μg/kg/min or nicardipine 5 μg/kg/min) has been used in most investigations involving endotracheal intubation or controlled hypotension. However, this loading dose was omitted in the present study because it has been associated with symptomatic hypotension [15] and the purpose of this study was to prevent hypertension, not to induce hypotension.
In the esmolol group, the hypotensive effect of esmolol was not obvious. Compared with the placebo group, MBP was significantly lower at just one time point (10 min after drug infusion, Fig. 1 ). In addition, 3 patients in the esmolol group required bolus doses of nicardipine due to uncontrolled hypertension despite esmolol infusion in the PACU. These findings are contrary to previous investigations [6, 16] in which an esmolol bolus or infusion attenuated HR and BP increases after tracheal extubation. The mechanism underlying these different hemodynamic responses to esmolol appear to be associated with different cardiovascular statuses, patient characteristics (e.g., young vs. old), or different modes of anesthesia (TIVA vs. inhalation anesthesia). During TIVA, propofol causes peripheral vasodilatation [17] and after its discontinuation, there might be a rebound increase in systemic vascular resistance. In addition, esmolol is associated with a profound decrease in cardiac output and reflex increase in systemic vascular resistance [18] . Taken together, the above suggests that esmolol may be ineffective at attenuating BP increases during emergence from TIVA.
In this study, MBP was significantly lower in the nicardipine group than in the other two groups until 10 min after terminating drug infusion, and it was restored in the ward. This finding is consistent with a previous investigation in which time to baseline BP restoration after nicardipine infusion was approximately 20 min [19] . In addition, the use of nicardipine infusion requires caution when administration is prolonged (about 270 ± 20 min) because nicardipine may have a cumulative effect, which may cause resistance to vasopressors [20] .
In the present study, the duration of nicardipine administration was 25 min, which is not associated with accumulation.
No differences in HR were observed between the nicardipine and the placebo group at any time point in this study. Diverse results have been reported regarding the effect of nicardipine on HR. A nicardipine bolus is known to cause tachycardia at emergence and tracheal extubation, because of a reduced systemic vascular resistance and reflex tachycardia [7, 8] . However, other investigators reported that bolus nicardipine administered to anesthetized patients did not increase HR [21] , which may have been due to an attenuation of reflex sympathetic activity.
In addition, it has been reported that no change in HR occurred during long-term hypotensive anesthesia with nicardipine infusion [20] . The reasons for these different hemodynamic responses to nicardipine seem to be associated with different modes of dosing (i.e., single bolus vs. continuous infusion without a loading dose) and/or different modes of anesthesia (inhalational anesthesia vs. TIVA).
Myocardial oxygen consumption (MVO2) was not measured in this study, but RPP is a good correlate of overall MVO2 [22] . In patients with myocardial ischemia, esmolol was found to effectively reduce HR and BP, and thereby decrease RPP [23] . In our study, RPP was significantly lower in the esmolol group than in the placebo group from 8 min after drug infusion, but was comparable between esmolol and nicardipine group. In addition, it has been reported that the greater selectivity of nicardipine for the coronary vasculature can increase myocardial oxygen supply [24] . Therefore, nicardipine can be administered safely without the risk of RPP increase in patients with ischemic heart disease to control BP. Nicardipine can also induce favorable cerebrovascular changes in stroke patients. These include cerebral vasospasm reversal, cerebral blood flow augmentation, and thus oxygen delivery, and the inhibition of platelet aggregation [24] . Therefore, it makes sense to administer nicardipine before emergence from TIVA to reduce the cerebrovascular risk in patients with cerebrovascular disease.
At the end of surgery, intravenous patient-controlled analgesia (PCA) infusion was not applied in this study, because post-thyroidectomy pain is considered to be relatively mild.
Moreover, skin infiltration with local anesthetic such as ropivacaine, as administered in this study, should decrease postoperative pain [25] . Although intraoperative esmolol is associated with decreased requirements in postoperative opioids [26] , no significant difference was observed among the three groups with respect to rescue analgesic requirements. In addition, we were set on preserving the double-blind design of this study. The difficulties associated with blinding investigators with respect to esmolol infusion has been previously described [27] , as it was expected that a decrease in HR in response to an esmolol loading dose would readily identify patients on esmolol.
In conclusion, the present study demonstrates that esmolol infusion (250 μg/kg/min) during emergence from TIVA attenuated HR increase but only marginally affected BP increases, whereas nicardipine infusion (2 μg/kg/min) mainly attenuated BP increase but did not affect HR or RPP. Accordingly, nicardipine infusion was found to be more effective than esmolol infusion at attenuating BP increases during emergence from TIVA with propofol and remifentanil.
